Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver D Howes

Showing results (281-290 of 329) with videos related to

Pageof 33
Sort By:
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Schizophrenia Bulletin|January 3, 2018
Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second CohortPaul Allen, Matilda Azis, Gemma Modinos, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Psychopharmacology|April 20, 2011
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET studyEuitae Kim, Oliver D Howes, Bo-Hyung Kim, et al.
Biological Psychiatry|February 9, 2025
Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for PsychosisSamuel R Knight, Leyla Abbasova, Yashar Zeighami, et al.
Biological Psychiatry|June 28, 2024
Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [<sup>18</sup>F]-DOPA Positron Emission Tomography StudyLuke J Vano, Robert A McCutcheon, Grazia Rutigliano, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Scientific Reports|July 23, 2022
A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine functionEnrico D'Ambrosio, Giulio Pergola, Antonio F Pardiñas, et al.
Molecular Psychiatry|May 9, 2020
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamineMichelle Kokkinou, Elaine E Irvine, David R Bonsall, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Pageof 33

Showing results (281-290 of 329) with videos related to

Sort By:
Pageof 33
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Schizophrenia Bulletin|January 3, 2018
Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second CohortPaul Allen, Matilda Azis, Gemma Modinos, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Psychopharmacology|April 20, 2011
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET studyEuitae Kim, Oliver D Howes, Bo-Hyung Kim, et al.
Biological Psychiatry|February 9, 2025
Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for PsychosisSamuel R Knight, Leyla Abbasova, Yashar Zeighami, et al.
Biological Psychiatry|June 28, 2024
Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [<sup>18</sup>F]-DOPA Positron Emission Tomography StudyLuke J Vano, Robert A McCutcheon, Grazia Rutigliano, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Scientific Reports|July 23, 2022
A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine functionEnrico D'Ambrosio, Giulio Pergola, Antonio F Pardiñas, et al.
Molecular Psychiatry|May 9, 2020
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamineMichelle Kokkinou, Elaine E Irvine, David R Bonsall, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Pageof 33